Member Info for maximillion69

Tyke68. Just a thought if t there is any deal with BP on the horizon wouldn’t TB want all his ducks in line prior ?

Https://x.com/iqai_ib/status/1732042482115051778?s=46

Sorry wrong link

https://x.com/heidyll/status/1732001112952037809?s=46

TB did tweet /X

Https://x.com/iqai_ib/status/1721989389562360302?s=46

Tyke68 yes it has been presented earlier

Https://www.proactiveinvestors.co.uk/companies/news/1035208/iq-ai-announces-positive-results-in-ongoing-gam-study-1035208.html

I tried selling other shares to top up here this morning while it was low No go with HL

Hl ?? Been playing up all day

Dare I say it TB and FAB selling into this , hopefully will be done soon.

Https://youtu.be/zML4Dk78lJM?si=4h38GZ_jt5pYblwo

A pulse

https://x.com/iqai_ib/status/1730587557870653728?s=46

Https://x.com/afcenergy/status/1730172232880517485?s=46

Hopefully the IB team are back in office today preparing a bit of news . 🤞

My only guess is Trading 212. Commission Free trading

Tyke an early email I received posted on here

It is up to the company to decide if they want to submit an RPD designation before they request a priority review voucher within their drug application. Submitting and having an RPD designation is not required before submitting a voucher request, however, many sponsors receive their designation before requesting a voucher.

The RPD designation request is reviewed and processed under the Office of Orphan Products Development and the Priority Review Voucher program is under the review division CDER or CBER.

If you haven’t already, I strongly recommend you review the RPD PRV guidance. This guidance outlines the process and requirements of these programs - https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rare-pediatric-disease-priority-review-vouchers

Thank you.

This is a response from office of orphan drug development

I wonder too Tyke68 August last year (half year report) last recalled mention

Https://x.com/iqai_ib/status/1727084044104675791?s=46

Https://x.com/iqai_ib/status/1725213951045353795?s=46

Https://academic.oup.com/neuro-oncology/article-abstract/25/Supplement_5/v89/7405564

Safe travels to @JenConnellyMD as she travels to #SNO2023 where she will present preliminary results of @IQAI_IB's sponsored phase 1 clinical trial.